S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
New CBOE “special perk” helps traders target income every weekend (Ad)
Energy traders: A rebound is coming
NetApp stock is about to hit 20-year highs
New CBOE “special perk” helps traders target income every weekend (Ad)
Ambarella: robust double-digit upside comes into focus
Retail sector resurgence: optimism grows for holiday momentum
New CBOE “special perk” helps traders target income every weekend (Ad)
Behind the tech boom: Big price leaders selectively laying off
These biotechs targeting multiple neurodegenerative diseases
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
New CBOE “special perk” helps traders target income every weekend (Ad)
Energy traders: A rebound is coming
NetApp stock is about to hit 20-year highs
New CBOE “special perk” helps traders target income every weekend (Ad)
Ambarella: robust double-digit upside comes into focus
Retail sector resurgence: optimism grows for holiday momentum
New CBOE “special perk” helps traders target income every weekend (Ad)
Behind the tech boom: Big price leaders selectively laying off
These biotechs targeting multiple neurodegenerative diseases
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
New CBOE “special perk” helps traders target income every weekend (Ad)
Energy traders: A rebound is coming
NetApp stock is about to hit 20-year highs
New CBOE “special perk” helps traders target income every weekend (Ad)
Ambarella: robust double-digit upside comes into focus
Retail sector resurgence: optimism grows for holiday momentum
New CBOE “special perk” helps traders target income every weekend (Ad)
Behind the tech boom: Big price leaders selectively laying off
These biotechs targeting multiple neurodegenerative diseases
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
New CBOE “special perk” helps traders target income every weekend (Ad)
Energy traders: A rebound is coming
NetApp stock is about to hit 20-year highs
New CBOE “special perk” helps traders target income every weekend (Ad)
Ambarella: robust double-digit upside comes into focus
Retail sector resurgence: optimism grows for holiday momentum
New CBOE “special perk” helps traders target income every weekend (Ad)
Behind the tech boom: Big price leaders selectively laying off
These biotechs targeting multiple neurodegenerative diseases

Senti Biosciences Stock Price, News & Analysis (NASDAQ:SNTI)

$0.44
+0.01 (+2.33%)
(As of 12/1/2023 ET)
Compare
Today's Range
$0.41
$0.45
50-Day Range
$0.28
$0.68
52-Week Range
$0.27
$2.37
Volume
202,649 shs
Average Volume
7.35 million shs
Market Capitalization
$19.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

Senti Biosciences MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
809.1% Upside
$4.00 Price Target
Short Interest
Bearish
5.71% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.44mentions of Senti Biosciences in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.59) to ($1.11) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.98 out of 5 stars

Medical Sector

634th out of 952 stocks

Biological Products, Except Diagnostic Industry

106th out of 164 stocks


SNTI stock logo

About Senti Biosciences Stock (NASDAQ:SNTI)

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

SNTI Stock Price History

SNTI Stock News Headlines

Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Senti Biosciences Inc SNTI
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Shanti Overseas India Ltd (SNTI)
Senti Bio to Participate in Upcoming Conferences
Expert Ratings for Senti Biosciences
See More Headlines
Receive SNTI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Senti Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
12/01/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/27/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SNTI
Fax
N/A
Employees
122
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.00
High Stock Price Target
$6.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+809.1%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-58,210,000.00
Net Margins
-2,692.82%
Pretax Margin
-3,609.96%

Debt

Sales & Book Value

Annual Sales
$4.29 million
Book Value
$1.86 per share

Miscellaneous

Free Float
38,977,000
Market Cap
$19.60 million
Optionable
Not Optionable
Beta
2.51
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Timothy K. Lu M.D. (Age 42)
    Ph.D., Co-founder, CEO, President & Director
    Comp: $811.26k
  • Dr. James J. Collins Ph.D. (Age 57)
    Scientific Co-Founder, Chairperson of Scientific Advisory Board & Independent Director
    Comp: $41.49k
  • Dr. Deborah A. Knobelman Ph.D. (Age 49)
    CFO, Head of Corporate Development & Treasurer
    Comp: $600.22k
  • Ms. Susan D. Berland (Age 68)
    Senior Financial Executive & Independent Director
    Comp: $54.23k
  • Dr. Kanya Rajangam M.D. (Age 50)
    Ph.D., Head of Research & Development and Chief Medical Officer
    Comp: $679.71k
  • Dr. Wilson Wong Ph.D.
    Scientific Co-Founder & Member of Scientific Advisory Board
  • Mr. Mike Rhee
    Senior VP of Legal Affairs & Corporate Secretary
  • Mr. Martin A. Giedlin Ph.D.
    Senior Vice President of Science Development
  • Susan Kahlert
    Controller














SNTI Stock Analysis - Frequently Asked Questions

Should I buy or sell Senti Biosciences stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Senti Biosciences in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" SNTI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SNTI, but not buy additional shares or sell existing shares.
View SNTI analyst ratings
or view top-rated stocks.

What is Senti Biosciences' stock price target for 2024?

3 brokerages have issued 12 month target prices for Senti Biosciences' shares. Their SNTI share price targets range from $2.00 to $6.00. On average, they expect the company's share price to reach $4.00 in the next year. This suggests a possible upside of 809.1% from the stock's current price.
View analysts price targets for SNTI
or view top-rated stocks among Wall Street analysts.

How have SNTI shares performed in 2023?

Senti Biosciences' stock was trading at $1.41 at the beginning of 2023. Since then, SNTI stock has decreased by 68.8% and is now trading at $0.44.
View the best growth stocks for 2023 here
.

Are investors shorting Senti Biosciences?

Senti Biosciences saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 1,500,000 shares, an increase of 260.1% from the October 31st total of 416,500 shares. Based on an average trading volume of 2,530,000 shares, the days-to-cover ratio is presently 0.6 days. Currently, 5.7% of the shares of the stock are short sold.
View Senti Biosciences' Short Interest
.

When is Senti Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024.
View our SNTI earnings forecast
.

What ETF holds Senti Biosciences' stock ?

ARK Genomic Revolution ETF holds 1,882,161 shares of SNTI stock, representing 0.08% of its portfolio.

Who are Senti Biosciences' major shareholders?

Senti Biosciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include TD Asset Management Inc (0.54%).
View institutional ownership trends
.

How do I buy shares of Senti Biosciences?

Shares of SNTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:SNTI) was last updated on 12/2/2023 by MarketBeat.com Staff

My Account -